We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+8.94%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.92%
AUM
$76.2B
AUM Growth
+$2.6B
(+3.5%)
Cap. Flow
-$2.97B
Cap. Flow
% of AUM
-3.9%
Top 10 Holdings %
Top 10 Hldgs %
21.61%
Holding
3,238
New
235
Increased
684
Reduced
2,065
Closed
243
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Core S&P 500 ETF
IVV
|
+$77.3M |
| 2 |
Blackstone
BX
|
+$53.2M |
| 3 |
NXP Semiconductors
NXPI
|
+$40.8M |
| 4 |
Palantir
PLTR
|
+$34.3M |
| 5 |
Snowflake
SNOW
|
+$24.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$206M |
| 2 |
Microsoft
MSFT
|
+$163M |
| 3 |
Linde
LIN
|
+$133M |
| 4 |
Amazon
AMZN
|
+$94.7M |
| 5 |
Alphabet (Google) Class C
GOOG
|
+$82.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 23.34% |
| 2 | Financials | 14.16% |
| 3 | Healthcare | 12.95% |
| 4 | Consumer Discretionary | 12.06% |
| 5 | Communication Services | 9.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2101
Krystal Biotech
KRYS
$9.66B
| $1.41M | ﹤0.01% |
20,684
+5,685
| +38% | +$397K |
|
2102
Weis Markets
WMK
$1.86B
| $1.41M | ﹤0.01% |
27,222
+5,309
| +24% | +$281K |
|
2103
Northern Oil and Gas
NOG
$2.35B
| $1.4M | ﹤0.01% |
+67,217
| New | +$1.1M |
|
|
RUBY
2104
DELISTED
Rubius Therapeutics, Inc
RUBY
| $1.39M | ﹤0.01% |
57,031
-9,810
| -15% | -$245K |
|
|
GLDD
2105
DELISTED
Great Lakes Dredge & Dock
GLDD
| $1.39M | ﹤0.01% |
95,060
-9,425
| -9% | -$139K |
|
2106
Winmark
WINA
$1.32B
| $1.39M | ﹤0.01% |
7,224
-236
| -3% | -$45.9K |
|
2107
MiMedx Group
MDXG
$633M
| $1.38M | ﹤0.01% |
+110,183
| New | +$1.19M |
|
2108
Travere Therapeutics
TVTX
$5.78B
| $1.38M | ﹤0.01% |
94,232
+25,563
| +37% | +$504K |
|
|
PING
2109
DELISTED
Ping Identity Holding Corp.
PING
| $1.38M | ﹤0.01% |
60,026
+19,754
| +49% | +$465K |
|
|
SHYF
2110
DELISTED
The Shyft Group
SHYF
| $1.37M | ﹤0.01% |
36,722
-3,377
| -8% | -$127K |
|
2111
Forrester Research
FORR
$228M
| $1.37M | ﹤0.01% |
29,899
-1,490
| -5% | -$64.3K |
|
2112
Celldex Therapeutics
CLDX
$3.27B
| $1.37M | ﹤0.01% |
+40,835
| New | +$1.12M |
|
2113
XPEL
XPEL
$1.38B
| $1.37M | ﹤0.01% |
16,292
-51
| -0.3% | -$3.76K |
|
2114
Johnson Outdoors
JOUT
$505M
| $1.36M | ﹤0.01% |
11,229
-1,152
| -9% | -$154K |
|
|
AVID
2115
DELISTED
Avid Technology Inc
AVID
| $1.36M | ﹤0.01% |
34,657
-1,483
| -4% | -$42.6K |
|
2116
Motorcar Parts of America
MPAA
$258M
| $1.35M | ﹤0.01% |
60,272
-4,796
| -7% | -$109K |
|
2117
SFL Corp
SFL
$1.61B
| $1.35M | ﹤0.01% |
176,833
-8,463
| -5% | -$69.3K |
|
|
EB
2118
DELISTED
Eventbrite
EB
| $1.35M | ﹤0.01% |
70,935
+3,118
| +5% | +$66.1K |
|
|
RAD
2119
DELISTED
Rite Aid Corporation
RAD
| $1.35M | ﹤0.01% |
82,651
-1,265
| -2% | -$24.2K |
|
2120
Center Bancorp
CNOB
$1.78B
| $1.34M | ﹤0.01% |
51,096
-6,454
| -11% | -$174K |
|
2121
Kymera Therapeutics
KYMR
$8.94B
| $1.34M | ﹤0.01% |
27,557
+16,141
| +141% | +$701K |
|
2122
Bristow Group
VTOL
$1.36B
| $1.33M | ﹤0.01% |
51,996
-1,364
| -3% | -$36.8K |
|
2123
Rayonier Advanced Materials
RYAM
$610M
| $1.33M | ﹤0.01% |
199,021
-15,703
| -7% | -$128K |
|
2124
Anavex Life Sciences
AVXL
$310M
| $1.33M | ﹤0.01% |
58,096
+7,503
| +15% | +$111K |
|
|
ECHO
2125
EchoStar
ECHO
$26.2B
| $1.33M | ﹤0.01% |
54,653
+4,704
| +9% | +$121K |
|
Similar funds
VAM
RhumbLine Advisers's Q2 2021 Portfolio in Review
As of Q2 2021, RhumbLine Advisers held 3,238 positions worth $76.2B, up 3.5% from $73.6B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
RhumbLine Advisers withdrew a net $2.97B in Q2 2021, closing 243 positions and reducing 2,065 holdings. Its most notable exit was Varian Medical Systems, Inc., an estimated $32.1M position sold in full.
By sector, the portfolio is most concentrated in Technology at 23% of assets, up from 23% a quarter earlier, followed by Financials and Healthcare.
Against the trend, RhumbLine Advisers opened a new position in DraftKings worth $14.2M.
- RhumbLine Advisers's largest Q2 2021 buy was DraftKings: 271,227 shares worth $14.2M.
- RhumbLine Advisers added most to iShares Core S&P 500 ETF in Q2 2021, an estimated $77.3M increase.
- RhumbLine Advisers's biggest Q2 2021 reduction was Apple, cutting an estimated $206M.
- RhumbLine Advisers fully exited Varian Medical Systems, Inc. in Q2 2021, selling an estimated $32.1M.
- RhumbLine Advisers's ten largest holdings make up 22% of its $76.2B portfolio in Q2 2021.
- RhumbLine Advisers opened 235 new positions and closed 243 in Q2 2021.
- RhumbLine Advisers's portfolio value rose 3.5% quarter-over-quarter to $76.2B.
Based on RhumbLine Advisers's 13F filing for Q2 2021, filed 5 Aug 2021.